Figure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Year: 2024
Type: other
Abstract: Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
Authors: Paul E. Oberstein, Andressa Dias Costa, Emily A. Kawaler, Victoire Cardot-Ruffino, Osama E. Rahma, Nina Beri, Harshabad Singh, Thomas A. Abrams, Leah H. Biller, James M. Cleary, Peter Enzinger, Brandon M. Huffman, Nadine J. McCleary, Kimberly J. Perez, Douglas A. Rubinson, Benjamin L. Schlechter, Rishi Surana, Matthew B. Yurgelun, S. Jennifer Wang, Joshua Remland, Lauren K. Brais, Naima Bollenrucher, Eugena Chang, Lestat R. Ali, Patrick J. Lenehan, Igor Dolgalev, Gregor Werba, Cibelle Lima, C. Elizabeth Keheler, Keri M. Sullivan, Michael Dougan, Cristina Hajdu, Maya Dajee, Marc R. Pelletier, Saloney Nazeer, Matthew Squires, Dafna Bar-Sagi, Brian M. Wolpin, Jonathan A. Nowak, Diane M. Simeone, Stephanie K. Dougan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402201631